Trial Profile
Bioequivalence of Two Different Polymorphs of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jul 2014
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Acute coronary syndromes; Deep vein thrombosis; Embolism; Stroke; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 02 Jul 2014 New trial record